标题：替吉奥联合康艾注射液治疗晚期非小细胞肺癌的疗效与安全性

      作者：杨君，郭晓辉，汪力慧
    (河北港口集团有限公司港口医院肿瘤科，河北 秦皇岛 066000)

      卷次： 2016年27卷7期

      【摘要】 目的 探讨替吉奥联合康艾注射液治疗晚期非小细胞肺癌(NSCLC)的疗效与安全性。方法 回顾
性分析2009年1月至2015年3月118例经一线和(或)二线化疗失败的晚期NSCLC患者。对照组22例，持续给予必
要的对症支持治疗。化疗组分为替吉奥组和联合治疗组，各48例。替吉奥按每日80 mg/m2，分两次口服。联合治
疗组与化疗同步联合应用康艾注射液 60 mL入5%葡萄糖或0.9%氯化钠注射液250 mL，静滴1次/d。化疗组以连
用 28 d，休息 14 d为一个周期。比较三组患者的总生存(OS)、无进展生存(PFS)、客观缓解率(ORR)、疾病控制率
(DCR)及不良反应和生活质量。结果 对照组与化疗组的中位OS分别为6.0个月和11.0个月，两组的中位PFS分
别为2.0个月和3.5个月(P<0.001)。化疗组的ORR分别为8.3% (4/48)和10.4% (5/48) (P=0.728)，DCR分别为37.5%
(18/48)和47.9% (23/48) (P=0.305)。化疗组的不良反应多为Ⅰ~Ⅱ度，替吉奥组中性粒细胞减少、贫血、厌食、腹泻、
乏力几方面的程度较联合治疗组明显，差异有统计学意义(P<0.05)。化疗组生活质量改善情况明显高于对照组(P<
0.001)；联合治疗组生活质量改善情况明显高于替吉奥组，差异有统计学意义(P=0.042)。结论 替吉奥治疗晚期
NSCLC有一定的疗效且不良反应可以耐受，联合康艾注射液可减轻化疗不良反应、改善生活质量。

      【关键词】 非小细胞肺癌；替吉奥；康艾注射液；化疗；疗效；安全性

      【中图分类号】 R734.2 【文献标识码】 A 【文章编号】 1003—6350（2016）07—1073—05


Efficacy and safety of S-1 combined with Kang'ai injection in the treatment of advanced non-small cell lung
cancer.
YANG Jun, GUO Xiao-hui, WANG Li-hui. Department of Oncology, Port Hospital of Hebei Port Group CO., LTD,
Qinhuangdao 066000, Hebei, CHINA

【Abstract】 Objective To investigate the efficacy and safety of S-1 combined with Kang'ai injection in the
treatment of advanced non-small cell lung cancer (NSCLC). Methods This retrospective study included 118 patients
from January 2009 to March 2015 with the failure of one or more regimens of systemic chemotherapy. The control group
included 22 patients given the necessary supportive treatment. The chemotherapy groups were divided into S-1 group
and combined treatment group, with 48 cases in each group. Patients in S-1 group received oral S-1 (80 mg/m2) in two
divided doses daily. Based on chemotherapy, the combined treatment group applied Kang'ai injection 60 mL in 5% glu-
cose or 0.9% sodium chloride injection 250 mL, intravenous drip once daily. S-1 was administered orally for 28 consecu-
tive days, followed by a 14-day rest period. The overall survival (OS), progression free survival (PFS), objective re-
sponse rate (ORR) and disease control rate (DCR) were observed and compared. The adverse reactions were analyzed
and quality of life was assessed. Results The median OS of the control group and the chemotherapy groups were 6.0
months and 11.0 months, and the median PFS were 11.0 months and 3.5 months, respectively (P<0.001). The ORR of che-
motherapy groups were 8.3% (4/48) and 10.4% (5/48) (P=0.728), and the DCR were 37.5% (18/48) and 47.9% (23/48)
(P=0.305), respectively. The adverse reactions were generallyⅠ~Ⅱ degree. The degree of leukopenia, anemia, anorex-
ia, diarrhea and fatigue in S-1 group was more significant than those in the combined treatment group, with statistically
significant difference (P<0.05). The improvement of quality of life in chemotherapy groups was significantly higher than
that in control group (P<0.001). And the improvement of quality of life in the combined treatment group was higher than
that in S-1 group, and the difference was statistically significant (P=0.042). Conclusion S-1 monotherapy is effica-
cious with acceptable toxicity in the treatment of NSCLC, and combining with Kang'ai injection can reduce the adverse
reaction of chemotherapy and improve the quality of life.

      【Key words】 Non-small cell lung cancer; S-I; Kang'ai injection; Chemotherapy; Efficacy; Safety
·论 著·
6350.2016.07.015